SynthesisEuropean radiology2026
Whole-body MRI for opportunistic cancer detection in asymptomatic individuals: a systematic review and meta-analysis.
Synthesis in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- How to implement a radiologist led whole-body MRI screening program.Radiology advances · 2026Review
- Privately paid, direct-to-consumer diagnostic testing: let the buyer beware.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- Recent Progress of Magnetic Nanomaterials with Enhanced Enzymatic Activities in Antitumor Therapy.International journal of molecular sciences · 2025Review
- Whole-body magnetic resonance imaging for cancer screening.Canadian family physician Medecin de famille canadienArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe rising global cancer burden underscores the need for efficient screening strategies. Whole-body magnetic resonance imaging (WB-MRI) has emerged as a promising modality for cancer screening, with growing use in research and commercial settings. This study aimed to evaluate the opportunistic cancer detection rate and the feasibility of WB-MRI in asymptomatic individuals. MATERIALS AND
methodsA systematic review and meta-analysis were conducted per PRISMA guidelines. A literature search was performed across multiple databases from January 2015 to April 2025. Eligible studies used WB-MRI for cancer detection in asymptomatic individuals. Studies were excluded if they combined WB-MRI with other imaging methods or included patients with active malignancy or comorbidities/genetic syndromes associated with increased cancer risk. Random-effects meta-analyses estimated pooled proportions of confirmed cancer diagnoses. Risk of bias was assessed using the ROBINS-I tool. Sensitivity and subgroup analyses, publication bias assessment, and meta-regression were performed.
resultsTen studies were included, comprising 9024 participants. The pooled detection rate for confirmed cancer was 1.57% (95% CI: 1.22-2.03%; I² = 31.3%). Results were robust in sensitivity and meta-regression analyses. No significant subgroup differences or publication bias were found. Most studies had a moderate to serious risk of bias.
conclusionAlthough WB-MRI shows potential as an opportunistic non-invasive cancer detection tool, modest detection rates, frequent incidental findings, unstandardized protocols, and lack of long-term outcome or cost-effectiveness data limit its current clinical utility. KEY POINTS: Question Can whole-body magnetic resonance imaging (WB-MRI) serve as an effective cancer detection tool for asymptomatic individuals across various clinical and geographic settings? Findings This meta-analysis of over 9000 asymptomatic individuals found a lack of information on cost-effectiveness, unstandardized protocols, a modest cancer detection rate and high rates of incidental findings. Clinical relevance Despite the need for effective cancer screening tools and growing popularity in commercial and research centers, whole-body MRI lacks sufficient diagnostic yield, follow-up reports and standardization for opportunistic cancer detection in asymptomatic individuals and may lead to unnecessary investigations.
Indexed as
Identifiers
40884613What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.